# MGC018 With or Without MGA012 in Advanced Solid Tumors

> **NCT03729596** · PHASE1,PHASE2 · TERMINATED · sponsor: **MacroGenics** · enrollment: 143 (actual)

## Conditions studied

- Squamous Cell Carcinoma of Head and Neck
- Triple Negative Breast Cancer
- Melanoma
- Advanced Solid Tumor, Adult
- Metastatic Castrate Resistant Prostate Cancer
- Non Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** vobramitamab duocarmazine

## Key facts

- **NCT ID:** NCT03729596
- **Lead sponsor:** MacroGenics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-21
- **Primary completion:** 2023-03-18
- **Final completion:** 2023-03-18
- **Target enrollment:** 143 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2025-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03729596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03729596, "MGC018 With or Without MGA012 in Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03729596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*